Akeso, Inc. (HKG:9926)

Market Cap	86.03B
Revenue (ttm)	2.26B
Net Income (ttm)	-547.53M
Shares Out	897.58M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	1,011.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,881,323
Average Volume	15,025,532
Open	96.40
Previous Close	95.45
Day's Range	92.10 - 98.45
52-Week Range	35.00 - 105.50
Beta	0.52
RSI	63.22
Earnings Date	May 28, 2025

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,035
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9926

Financial Performance

Financial numbers in CNY